Clinical Trials Logo

Clinical Trial Summary

This is a Phase III, randomized, double-masked, active-controlled, parallel-group, multi-center study. Subjects diagnosed with glaucoma or OHT who meet eligibility criteria at Visit 1 (Screening) will washout of their current topical IOP-lowering medication(s), if any. After completing the required washout period, subjects will return for Visit 2 (Baseline, Day 1). Subjects who meet all eligibility criteria at baseline will be randomized to receive double-masked treatment for 3 months. Adult subjects will receive open-label DE-117 Ophthalmic Solution for an additional 9 months. Approximately 400 adult subjects and up to 30 pediatric subjects with glaucoma or OHT who meet all eligibility criteria will be randomized in a 1:1 ratio to receive either: - DE-117 Ophthalmic Solution once daily and Vehicle once daily, or - Timolol Maleate Ophthalmic Solution 0.5% twice daily. The study will evaluate the efficacy and safety of DE-117 Ophthalmic Solution compared with Timolol Maleate Ophthalmic Solution 0.5% in subjects with glaucoma or OHT through Month 3 and will provide additional safety data through Month 12 for subjects receiving DE-117.


Clinical Trial Description

n/a


Study Design


Related Conditions & MeSH terms


NCT number NCT03691649
Study type Interventional
Source Santen Inc.
Contact
Status Completed
Phase Phase 3
Start date September 14, 2018
Completion date September 3, 2020

See also
  Status Clinical Trial Phase
Recruiting NCT04967989 - Clarifying the Optimal Application of SLT Therapy Trial Phase 3
Completed NCT03691662 - A Phase III Study Assessing the Efficacy and Safety of DE-117 Ophthalmic Solution Compared With Timolol Maleate Ophthalmic Solution 0.5% in Subjects With Glaucoma or Ocular Hypertension - Spectrum 4 Study Phase 3
Completed NCT01687426 - Study Evaluating the Safety and Intraocular Pressure (IOP) Lowering Response of Brimonidine Tartrate Ophthalmic Solution in Subjects With Open Angle Glaucoma or Ocular Hypertension Phase 1
Completed NCT05181046 - Evaluation of Nanodropper-mediated Microdrops vs. Standard Drops of 0.5% Timolol Maleate in Glaucoma Patients N/A
Enrolling by invitation NCT02209961 - Combined Ex-PRESS Implantation Alone or With Phacoemulsification for Glaucoma Associated With Cataract N/A
Completed NCT03187418 - Treatment Outcomes of MicroPulse Trans-scleral Cyclophotocoagulation in Uncontrolled Glaucoma N/A
Completed NCT01654484 - A Study Assessing the Safety and Efficacy of DE-117 Ophthalmic Solution in Patients With POAG or OHT Phase 1/Phase 2
Completed NCT02371746 - Safety and Efficacy of ENV515 Travoprost Extended Release (XR) in Patients With Bilateral Ocular Hypertension or Primary Open Angle Glaucoma Phase 2
Completed NCT03927118 - Effect of Dexamethasone Implant on Optic Disc
Recruiting NCT04337944 - Endoscopic Assisted Anterior Hyaloid Peeling in Boston Type 1 Keratoprosthesis (KPro-HP-Endo) N/A
Terminated NCT02231515 - Prospective,Randomized,Controlled Study to Assess Efficacy,Safety, and Tolerability of SLT vs. PLT in Patients With POAG N/A